{"id":43866,"date":"2025-10-20T19:09:46","date_gmt":"2025-10-20T11:09:46","guid":{"rendered":"https:\/\/flcube.com\/?p=43866"},"modified":"2025-10-20T19:09:47","modified_gmt":"2025-10-20T11:09:47","slug":"fosun-kairos-secures-series-a-financing-to-propel-cell%e2%80%91therapy-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43866","title":{"rendered":"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion"},"content":{"rendered":"\n<p><strong>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>) announced that the <strong>Shenzhen Biopharmaceutical Industry Fund<\/strong> will participate in a <strong>Series\u202fA financing<\/strong> of its controlling subsidiary, <strong>Fosun Kairos<\/strong>. The fund will invest up to <strong>RMB\u202f600\u202fmillion<\/strong> in tranches, subscribing for no more than <strong>RMB\u202f524,437,452<\/strong> of new registered capital in FosunKairos. Proceeds will finance operations and business development of Fosun Kairos and\/or its subsidiaries.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-amp-financial-snapshot\">Company &amp; Financial Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Investor<\/strong><\/td><td>Shenzhen Biopharmaceutical Industry Fund<\/td><\/tr><tr><td><strong>Investment<\/strong><\/td><td>RMB\u202f600\u202fmillion (tranches)<\/td><\/tr><tr><td><strong>Capital Commitment<\/strong><\/td><td>Up to RMB\u202f524,437,452<\/td><\/tr><tr><td><strong>Pre\u2011Money Valuation<\/strong><\/td><td>RMB\u202f2.2\u202fbillion<\/td><\/tr><tr><td><strong>Use of Funds<\/strong><\/td><td>Operations &amp; business development of FosunKairos &amp; subsidiaries<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fosun-kairos-a-pioneer-in-cell-therapy\">Fosun Kairos \u2013 A Pioneer in Cell\u2011Therapy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded<\/strong> \u2013 April\u202f2017<\/li>\n\n\n\n<li><strong>Core Focus<\/strong> \u2013 R&amp;D, manufacturing, and commercialization of cell\u2011therapy products<\/li>\n\n\n\n<li><strong>Flagship Product<\/strong> \u2013 <strong>Axicabtagene\u202fCiloleucel Injection<\/strong> (first CAR\u2011T therapy approved for marketing in China)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-approved-indications-as-of-17-oct-2025\">Approved Indications (as of 17\u202fOct\u202f2025)<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Relapsed or refractory large B\u2011cell lymphoma (r\/r\u202fLBCL)<\/strong> after \u2265\u202f2 lines of systemic therapy<\/li>\n\n\n\n<li><strong>LBCL refractory to first\u2011line chemoimmunotherapy<\/strong> or relapsing within 12\u202fmonths of first\u2011line therapy<\/li>\n<\/ol>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Ongoing Program<\/strong> \u2013 Third indication (relapsed\/refractory indolent non\u2011Hodgkin lymphoma) in bridging clinical trial phase; included in China\u2019s Breakthrough Therapy Designation program (excluding HK, Macau, TW).<\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-impact\">Strategic Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Infusion<\/strong> \u2013 Enables accelerated development of next\u2011generation CAR\u2011T and other cell\u2011therapy platforms.<\/li>\n\n\n\n<li><strong>Market Positioning<\/strong> \u2013 Strengthens Fosun Kairos\u2019 leadership in China\u2019s rapidly expanding cell\u2011therapy market.<\/li>\n\n\n\n<li><strong>Investor Confidence<\/strong> \u2013 The Shenzhen fund\u2019s commitment underscores confidence in FosunKairos\u2019 pipeline and commercial strategy.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/600196_20251018_QM6C.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20251018_QM6C.\"><\/object><a id=\"wp-block-file--media-58ec6439-2ed7-45b4-956d-9a219fdf950b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/600196_20251018_QM6C.pdf\">600196_20251018_QM6C<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/600196_20251018_QM6C.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-58ec6439-2ed7-45b4-956d-9a219fdf950b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43868,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4370,159,892],"class_list":["post-43866","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-fosun-kairos","tag-fosun-pharmaceutical","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund will participate in a Series\u202fA financing of its controlling subsidiary, Fosun Kairos. The fund will invest up to RMB\u202f600\u202fmillion in tranches, subscribing for no more than RMB\u202f524,437,452 of new registered capital in FosunKairos. Proceeds will finance operations and business development of Fosun Kairos and\/or its subsidiaries.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43866\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund will participate in a Series\u202fA financing of its controlling subsidiary, Fosun Kairos. The fund will invest up to RMB\u202f600\u202fmillion in tranches, subscribing for no more than RMB\u202f524,437,452 of new registered capital in FosunKairos. Proceeds will finance operations and business development of Fosun Kairos and\/or its subsidiaries.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43866\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-20T11:09:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-20T11:09:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2006.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43866#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43866\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion\",\"datePublished\":\"2025-10-20T11:09:46+00:00\",\"dateModified\":\"2025-10-20T11:09:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43866\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43866#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2006.webp\",\"keywords\":[\"Fosun Kairos\",\"Fosun Pharmaceutical\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43866#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43866\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43866\",\"name\":\"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43866#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43866#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2006.webp\",\"datePublished\":\"2025-10-20T11:09:46+00:00\",\"dateModified\":\"2025-10-20T11:09:47+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund will participate in a Series\u202fA financing of its controlling subsidiary, Fosun Kairos. The fund will invest up to RMB\u202f600\u202fmillion in tranches, subscribing for no more than RMB\u202f524,437,452 of new registered capital in FosunKairos. Proceeds will finance operations and business development of Fosun Kairos and\\\/or its subsidiaries.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43866#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43866\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43866#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2006.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2006.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43866#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund will participate in a Series\u202fA financing of its controlling subsidiary, Fosun Kairos. The fund will invest up to RMB\u202f600\u202fmillion in tranches, subscribing for no more than RMB\u202f524,437,452 of new registered capital in FosunKairos. Proceeds will finance operations and business development of Fosun Kairos and\/or its subsidiaries.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43866","og_locale":"en_US","og_type":"article","og_title":"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion","og_description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund will participate in a Series\u202fA financing of its controlling subsidiary, Fosun Kairos. The fund will invest up to RMB\u202f600\u202fmillion in tranches, subscribing for no more than RMB\u202f524,437,452 of new registered capital in FosunKairos. Proceeds will finance operations and business development of Fosun Kairos and\/or its subsidiaries.","og_url":"https:\/\/flcube.com\/?p=43866","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-20T11:09:46+00:00","article_modified_time":"2025-10-20T11:09:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2006.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43866#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43866"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion","datePublished":"2025-10-20T11:09:46+00:00","dateModified":"2025-10-20T11:09:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43866"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43866#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2006.webp","keywords":["Fosun Kairos","Fosun Pharmaceutical","SHA: 600196"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43866#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43866","url":"https:\/\/flcube.com\/?p=43866","name":"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43866#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43866#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2006.webp","datePublished":"2025-10-20T11:09:46+00:00","dateModified":"2025-10-20T11:09:47+00:00","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund will participate in a Series\u202fA financing of its controlling subsidiary, Fosun Kairos. The fund will invest up to RMB\u202f600\u202fmillion in tranches, subscribing for no more than RMB\u202f524,437,452 of new registered capital in FosunKairos. Proceeds will finance operations and business development of Fosun Kairos and\/or its subsidiaries.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43866#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43866"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43866#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2006.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2006.webp","width":1080,"height":608,"caption":"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43866#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Kairos Secures Series\u202fA Financing to Propel Cell\u2011Therapy Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2006.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43866"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43866\/revisions"}],"predecessor-version":[{"id":43869,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43866\/revisions\/43869"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43868"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}